Medications Associated with Gynaecomastia

Gynaecomastia, the enlargement of male breast tissue, can be caused by various medications. Spironolactone, ciclosporin, cimetidine, and omeprazole are some of the drugs that have been associated with this condition. Ramipril has also been linked to gynaecomastia, but it is a rare occurrence.

Aside from these medications, other drugs that can cause gynaecomastia include digoxin, LHRH analogues, cimetidine, and finasteride. It is important to note that not all individuals who take these medications will develop gynaecomastia, and the risk may vary depending on the dosage and duration of treatment.

The movement of glucose into cells requires insulin. In this case, the patient is likely suffering from type 1 diabetes mellitus or latent autoimmune diabetes in adults (LADA) with low c-peptide levels, indicating a complete lack of insulin. As a result, insulin is unable to stimulate the expression of GLUT-4, which significantly reduces the uptake of glucose into skeletal and adipose cells.

The patient’s low GLUT-1 expression is unlikely to be the cause of hyperglycemia. GLUT-1 is primarily expressed in fetal tissues and has a higher affinity for oxygen, allowing fetal cells to survive even in hypoglycemic conditions.

GLUT-2 expression is mainly found in hepatocytes and beta-cells of the pancreas. It allows for the bi-directional movement of glucose, equalizing glucose concentrations inside and outside the cell membrane, and enabling glucose-sensitive cells to measure serum glucose levels and respond accordingly.

GLUT-3 expression is mainly found in neuronal cells and has a high affinity, similar to GLUT-1. This allows for the survival of brain cells in hypoglycemic conditions.

Insulin is a hormone produced by the pancreas that plays a crucial role in regulating the metabolism of carbohydrates and fats in the body. It works by causing cells in the liver, muscles, and fat tissue to absorb glucose from the bloodstream, which is then stored as glycogen in the liver and muscles or as triglycerides in fat cells. The human insulin protein is made up of 51 amino acids and is a dimer of an A-chain and a B-chain linked together by disulfide bonds. Pro-insulin is first formed in the rough endoplasmic reticulum of pancreatic beta cells and then cleaved to form insulin and C-peptide. Insulin is stored in secretory granules and released in response to high levels of glucose in the blood. In addition to its role in glucose metabolism, insulin also inhibits lipolysis, reduces muscle protein loss, and increases cellular uptake of potassium through stimulation of the Na+/K+ ATPase pump.

Medullary thyroid cancer, hypercalcaemia, and phaeochromocytoma are associated with multiple endocrine neoplasia type IIa. The most frequent occurrence in this condition is medullary thyroid cancer, while hyperplasia is the most common lesion in the parathyroid glands. In contrast, parathyroid adenoma is the most common lesion in MEN I.

Understanding Multiple Endocrine Neoplasia

Multiple endocrine neoplasia (MEN) is an autosomal dominant disorder that affects the endocrine system. There are three main types of MEN, each with its own set of associated features. MEN type I is characterized by the 3 P’s: parathyroid hyperplasia leading to hyperparathyroidism, pituitary tumors, and pancreatic tumors such as insulinomas and gastrinomas. MEN type IIa is associated with the 2 P’s: parathyroid hyperplasia leading to hyperparathyroidism and phaeochromocytoma, as well as medullary thyroid cancer. MEN type IIb is characterized by phaeochromocytoma, medullary thyroid cancer, and a marfanoid body habitus.

The most common presentation of MEN is hypercalcaemia, which is often seen in MEN type I due to parathyroid hyperplasia. MEN type IIa and IIb are both associated with medullary thyroid cancer, which is caused by mutations in the RET oncogene. MEN type I is caused by mutations in the MEN1 gene. Understanding the different types of MEN and their associated features is important for early diagnosis and management of this rare but potentially serious condition.

Dopamine consistently prevents the release of prolactin.

Understanding Prolactin and Its Functions

Prolactin is a hormone that is produced by the anterior pituitary gland. Its primary function is to stimulate breast development and milk production in females. During pregnancy, prolactin levels increase to support the growth and development of the mammary glands. It also plays a role in reducing the pulsatility of gonadotropin-releasing hormone (GnRH) at the hypothalamic level, which can block the action of luteinizing hormone (LH) on the ovaries or testes.

The secretion of prolactin is regulated by dopamine, which constantly inhibits its release. However, certain factors can increase or decrease prolactin secretion. For example, prolactin levels increase during pregnancy, in response to estrogen, and during breastfeeding. Additionally, stress, sleep, and certain drugs like metoclopramide and antipsychotics can also increase prolactin secretion. On the other hand, dopamine and dopaminergic agonists can decrease prolactin secretion.

Overall, understanding the functions and regulation of prolactin is important for reproductive health and lactation.

The adrenal gland’s zona fasciculata produces cortisol, with a relative glucocorticoid activity of 1. Prednisolone has a relative glucocorticoid activity of 4, while dexamethasone has a relative glucocorticoid activity of 25.

Cortisol: Functions and Regulation

Cortisol is a hormone produced in the zona fasciculata of the adrenal cortex. It plays a crucial role in various bodily functions and is essential for life. Cortisol increases blood pressure by up-regulating alpha-1 receptors on arterioles, allowing for a normal response to angiotensin II and catecholamines. However, it inhibits bone formation by decreasing osteoblasts, type 1 collagen, and absorption of calcium from the gut, while increasing osteoclastic activity. Cortisol also increases insulin resistance and metabolism by increasing gluconeogenesis, lipolysis, and proteolysis. It inhibits inflammatory and immune responses, but maintains the function of skeletal and cardiac muscle.

The regulation of cortisol secretion is controlled by the hypothalamic-pituitary-adrenal (HPA) axis. The pituitary gland secretes adrenocorticotropic hormone (ACTH), which stimulates the adrenal cortex to produce cortisol. The hypothalamus releases corticotrophin-releasing hormone (CRH), which stimulates the pituitary gland to release ACTH. Stress can also increase cortisol secretion.

Excess cortisol in the body can lead to Cushing’s syndrome, which can cause a range of symptoms such as weight gain, muscle weakness, and high blood pressure. Understanding the functions and regulation of cortisol is important for maintaining overall health and preventing hormonal imbalances.

Corticosteroids are a class of medications commonly prescribed for various clinical uses, such as treating allergies, inflammatory conditions, auto-immunity, and endogenous steroid replacement.

There are different types of corticosteroids, each with varying levels of glucocorticoid and mineralocorticoid activity. Glucocorticoids mimic cortisol, which is involved in carbohydrate metabolism and the stress response, while mineralocorticoids mimic aldosterone, which regulates sodium and water retention in response to low blood pressure.

The clinical uses and side effects of corticosteroids depend on their level of glucocorticoid and mineralocorticoid activity. Fludrocortisone, for example, has minimal glucocorticoid activity and high mineralocorticoid activity.

Therefore, fluid retention is the most associated side effect with mineralocorticoid activity, while depression, hyperglycemia, osteoporosis, and peptic ulceration are side effects associated with glucocorticoid activity.

Corticosteroids are commonly prescribed medications that can be taken orally or intravenously, or applied topically. They mimic the effects of natural steroids in the body and can be used to replace or supplement them. However, the use of corticosteroids is limited by their numerous side effects, which are more common with prolonged and systemic use. These side effects can affect various systems in the body, including the endocrine, musculoskeletal, gastrointestinal, ophthalmic, and psychiatric systems. Some of the most common side effects include impaired glucose regulation, weight gain, osteoporosis, and increased susceptibility to infections. Patients on long-term corticosteroids should have their doses adjusted during intercurrent illness, and the medication should not be abruptly withdrawn to avoid an Addisonian crisis. Gradual withdrawal is recommended for patients who have received high doses or prolonged treatment.

The site of action for antidiuretic hormone (ADH) is the collecting ducts in the kidneys. A diagnosis of cranial diabetes insipidus, which can occur after head trauma, is confirmed by low urine osmolalities. In this condition, there is a deficiency of ADH, which is synthesized in the hypothalamus but acts on the collecting ducts to promote water reabsorption. Therefore, the hypothalamus is not the site of action for ADH, despite being where it is synthesized. The Loop of Henle and proximal convoluted tubule are also not the primary sites of action for ADH. ADH is released from the posterior pituitary gland, but its action occurs in the collecting ducts.

Understanding Antidiuretic Hormone (ADH)

Antidiuretic hormone (ADH) is a hormone that is produced in the supraoptic nuclei of the hypothalamus and released by the posterior pituitary gland. Its primary function is to conserve body water by promoting water reabsorption in the collecting ducts of the kidneys through the insertion of aquaporin-2 channels.

ADH secretion is regulated by various factors. An increase in extracellular fluid osmolality, a decrease in volume or pressure, and the presence of angiotensin II can all increase ADH secretion. Conversely, a decrease in extracellular fluid osmolality, an increase in volume, a decrease in temperature, or the absence of ADH can decrease its secretion.

Diabetes insipidus (DI) is a condition that occurs when there is either a deficiency of ADH (cranial DI) or an insensitivity to ADH (nephrogenic DI). Cranial DI can be treated with desmopressin, which is an analog of ADH.

Overall, understanding the role of ADH in regulating water balance in the body is crucial for maintaining proper hydration and preventing conditions like DI.

Understanding Waterhouse-Friderichsen Syndrome

Waterhouse-Friderichsen syndrome is a condition that occurs when the adrenal glands fail due to a previous adrenal haemorrhage caused by a severe bacterial infection. The most common cause of this condition is Neisseria meningitidis, but it can also be caused by other bacteria such as Haemophilus influenzae, Pseudomonas aeruginosa, Escherichia coli, and Streptococcus pneumoniae.

The symptoms of Waterhouse-Friderichsen syndrome are similar to those of hypoadrenalism, including lethargy, weakness, anorexia, nausea and vomiting, and weight loss. Other symptoms may include hyperpigmentation, especially in the palmar creases, vitiligo, and loss of pubic hair in women. In severe cases, a crisis may occur, which can lead to collapse, shock, and pyrexia.

Calcitonin is used in clinical practice to detect recurrence of medullary thyroid cancer. Thyroid function tests are not used for diagnosis or follow-up of malignancies. However, regular monitoring of TSH levels may be necessary for patients taking thyroxine.

Thyroid cancer rarely causes hyperthyroidism or hypothyroidism as it does not usually secrete thyroid hormones. The most common type of thyroid cancer is papillary carcinoma, which is often found in young females and has an excellent prognosis. Follicular carcinoma is less common, while medullary carcinoma is a cancer of the parafollicular cells that secrete calcitonin and is associated with multiple endocrine neoplasia type 2. Anaplastic carcinoma is rare and not responsive to treatment, causing pressure symptoms. Lymphoma is also rare and associated with Hashimoto’s thyroiditis.

Management of papillary and follicular cancer involves a total thyroidectomy followed by radioiodine to kill residual cells. Yearly thyroglobulin levels are monitored to detect early recurrent disease. Papillary carcinoma usually contains a mixture of papillary and colloid filled follicles, while follicular adenoma presents as a solitary thyroid nodule and malignancy can only be excluded on formal histological assessment. Follicular carcinoma may appear macroscopically encapsulated, but microscopically capsular invasion is seen. Medullary carcinoma is associated with raised serum calcitonin levels and familial genetic disease in up to 20% of cases. Anaplastic carcinoma is most common in elderly females and is treated by resection where possible, with palliation achieved through isthmusectomy and radiotherapy. Chemotherapy is ineffective.

The water deprivation test is a diagnostic tool used to assess patients with polydipsia, or excessive thirst. During the test, the patient is instructed to refrain from drinking water, and their bladder is emptied. Hourly measurements of urine and plasma osmolalities are taken to monitor changes in the body’s fluid balance. The results of the test can help identify the underlying cause of the patient’s polydipsia. Normal results show a high urine osmolality after the administration of DDAVP, while psychogenic polydipsia is characterized by a low urine osmolality. Cranial DI and nephrogenic DI are both associated with high plasma osmolalities and low urine osmolalities.

The most frequent cause of Waterhouse-Friderichsen syndrome is Neisseria meningitidis. This syndrome is characterized by adrenal gland failure caused by bleeding into the adrenal gland. Although any organism that can induce disseminated intravascular coagulation can lead to adrenal haemorrhage, neisseria meningitidis is the most common cause and therefore the answer.

Understanding Waterhouse-Friderichsen Syndrome

Waterhouse-Friderichsen syndrome is a condition that occurs when the adrenal glands fail due to a previous adrenal haemorrhage caused by a severe bacterial infection. The most common cause of this condition is Neisseria meningitidis, but it can also be caused by other bacteria such as Haemophilus influenzae, Pseudomonas aeruginosa, Escherichia coli, and Streptococcus pneumoniae.

The symptoms of Waterhouse-Friderichsen syndrome are similar to those of hypoadrenalism, including lethargy, weakness, anorexia, nausea and vomiting, and weight loss. Other symptoms may include hyperpigmentation, especially in the palmar creases, vitiligo, and loss of pubic hair in women. In severe cases, a crisis may occur, which can lead to collapse, shock, and pyrexia.

During the postnatal period, Graves’ disease may either present for the first time or worsen. Exophthalmos is a distinctive symptom of Graves’ disease that is not observed in other hyperthyroid conditions. Hypothyroidism is caused by Hashimoto’s thyroiditis. postpartum thyroiditis is characterized by initial hyperthyroidism after childbirth, followed by normal or occasionally reduced thyroid levels.

During pregnancy, there is an increase in the levels of thyroxine-binding globulin (TBG), which causes an increase in the levels of total thyroxine. However, this does not affect the free thyroxine level. If left untreated, thyrotoxicosis can increase the risk of fetal loss, maternal heart failure, and premature labor. Graves’ disease is the most common cause of thyrotoxicosis during pregnancy, but transient gestational hyperthyroidism can also occur due to the activation of the TSH receptor by HCG. Propylthiouracil has traditionally been the antithyroid drug of choice, but it is associated with an increased risk of severe hepatic injury. Therefore, NICE Clinical Knowledge Summaries recommend using propylthiouracil in the first trimester and switching to carbimazole in the second trimester. Maternal free thyroxine levels should be kept in the upper third of the normal reference range to avoid fetal hypothyroidism. Thyrotropin receptor stimulating antibodies should be checked at 30-36 weeks gestation to determine the risk of neonatal thyroid problems. Block-and-replace regimes should not be used in pregnancy, and radioiodine therapy is contraindicated.

On the other hand, thyroxine is safe during pregnancy, and serum thyroid-stimulating hormone should be measured in each trimester and 6-8 weeks postpartum. Women require an increased dose of thyroxine during pregnancy, up to 50% as early as 4-6 weeks of pregnancy. Breastfeeding is safe while on thyroxine. It is important to manage thyroid problems during pregnancy to ensure the health of both the mother and the baby.

Cortisol: Functions and Regulation

Cortisol is a hormone produced in the zona fasciculata of the adrenal cortex. It plays a crucial role in various bodily functions and is essential for life. Cortisol increases blood pressure by up-regulating alpha-1 receptors on arterioles, allowing for a normal response to angiotensin II and catecholamines. However, it inhibits bone formation by decreasing osteoblasts, type 1 collagen, and absorption of calcium from the gut, while increasing osteoclastic activity. Cortisol also increases insulin resistance and metabolism by increasing gluconeogenesis, lipolysis, and proteolysis. It inhibits inflammatory and immune responses, but maintains the function of skeletal and cardiac muscle.

The regulation of cortisol secretion is controlled by the hypothalamic-pituitary-adrenal (HPA) axis. The pituitary gland secretes adrenocorticotropic hormone (ACTH), which stimulates the adrenal cortex to produce cortisol. The hypothalamus releases corticotrophin-releasing hormone (CRH), which stimulates the pituitary gland to release ACTH. Stress can also increase cortisol secretion.

Excess cortisol in the body can lead to Cushing’s syndrome, which can cause a range of symptoms such as weight gain, muscle weakness, and high blood pressure. Understanding the functions and regulation of cortisol is important for maintaining overall health and preventing hormonal imbalances.

Diagnosis and Management of Primary Hypothyroidism

The patient’s test results indicate a case of primary hypothyroidism, characterized by low levels of thyroxine (T4) and elevated thyroid-stimulating hormone (TSH). The most likely cause of this condition is Hashimoto’s thyroiditis, which is often accompanied by the presence of thyroid peroxidase antibodies. While the patient has a goitre, it appears to be smooth and non-threatening, so a thyroid ultrasound is not necessary. Additionally, a radio-iodine uptake scan is unlikely to show significant uptake and is therefore not recommended. Positive TSH receptor antibodies are typically associated with Graves’ disease, which is not the likely diagnosis in this case. For further information on Hashimoto’s thyroiditis, patients can refer to Patient.info.

Acromegaly is a condition that results from an excess of growth hormone, which can cause a person to have a coarse facial appearance, a larger tongue, and excessive sweating and oily skin. This condition is often caused by a pituitary adenoma.

If a person has an excess of insulin, they may experience hypoglycemia and confusion. This can occur in cases of factitious illness, over-administration of insulin in diabetics, and insulinomas (neuroendocrine pancreatic tumors).

An excess of glucagon can cause hyperglycemia. Glucagon is secreted by alpha cells in the pancreas and is often elevated in cases of glucagonomas (neuroendocrine pancreatic tumors).

An excess of thyroid-stimulating hormone can be seen in cases of primary hypothyroidism and secondary hyperthyroidism.

Acromegaly is a condition characterized by excess growth hormone, which is usually caused by a pituitary adenoma in over 95% of cases. However, in some cases, it can be caused by ectopic GHRH or GH production by tumors, such as those found in the pancreas. The condition is associated with a number of physical features, including a coarse facial appearance, spade-like hands, and an increase in shoe size. Other features include a large tongue, prognathism, interdental spaces, excessive sweating, and oily skin, which are caused by sweat gland hypertrophy. In some cases, patients may also experience hypopituitarism, headaches, bitemporal hemianopia, and raised prolactin levels, which can lead to galactorrhea. Approximately 6% of patients with acromegaly also have MEN-1.

Complications associated with acromegaly include hypertension, diabetes (which affects over 10% of patients), cardiomyopathy, and colorectal cancer. It is important to diagnose and treat acromegaly early to prevent these complications from developing.

The man’s initial symptoms are consistent with a diagnosis of phaeochromocytoma, a type of neuroendocrine tumor that affects the chromaffin cells in the adrenal medulla. This condition leads to an overproduction of adrenaline and noradrenaline, resulting in an excessive sympathetic response.

Calcitonin is secreted by the parafollicular C cells in the thyroid gland.

The anterior pituitary gland contains gonadotropes, lactotropes, and thyrotropes, which secrete gonadotropins (FSH, LH), prolactin, and TSH, respectively.

Phaeochromocytoma: A Rare Tumor that Secretes Catecholamines

Phaeochromocytoma is a type of tumor that secretes catecholamines and is considered rare. It is familial in about 10% of cases and may be associated with certain syndromes such as MEN type II, neurofibromatosis, and von Hippel-Lindau syndrome. This tumor can be bilateral in 10% of cases and malignant in 10%. It can also occur outside of the adrenal gland, with the most common site being the organ of Zuckerkandl, which is adjacent to the bifurcation of the aorta.

The symptoms of phaeochromocytoma are typically episodic and include hypertension (which is present in around 90% of cases and may be sustained), headaches, palpitations, sweating, and anxiety. To diagnose this condition, a 24-hour urinary collection of metanephrines is preferred over a 24-hour urinary collection of catecholamines due to its higher sensitivity (97%).

Surgery is the definitive management for phaeochromocytoma. However, before surgery, the patient must first be stabilized with medical management, which includes an alpha-blocker (such as phenoxybenzamine) given before a beta-blocker (such as propranolol).

DPP-4 inhibitors, also known as gliptins, function by decreasing the breakdown of incretins like GLP-1 in the periphery. This leads to an increase in incretin levels, which in turn lowers blood glucose levels.

It is important to note that increasing the peripheral breakdown of incretin would have the opposite effect and worsen glycaemic control.

Metformin, on the other hand, works by enhancing the uptake of insulin in the periphery.

Reducing the secretion of insulin from the pancreas would not be an effective mechanism and would actually raise glucose levels in the blood.

SGLT2 inhibitors, such as dapagliflozin, function by reducing the reabsorption of glucose in the kidneys.

Diabetes mellitus is a condition that has seen the development of several drugs in recent years. One hormone that has been the focus of much research is glucagon-like peptide-1 (GLP-1), which is released by the small intestine in response to an oral glucose load. In type 2 diabetes mellitus (T2DM), insulin resistance and insufficient B-cell compensation occur, and the incretin effect, which is largely mediated by GLP-1, is decreased. GLP-1 mimetics, such as exenatide and liraglutide, increase insulin secretion and inhibit glucagon secretion, resulting in weight loss, unlike other medications. They are sometimes used in combination with insulin in T2DM to minimize weight gain. Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as vildagliptin and sitagliptin, increase levels of incretins by decreasing their peripheral breakdown, are taken orally, and do not cause weight gain. Nausea and vomiting are the major adverse effects of GLP-1 mimetics, and the Medicines and Healthcare products Regulatory Agency has issued specific warnings on the use of exenatide, reporting that it has been linked to severe pancreatitis in some patients. NICE guidelines suggest that a DPP-4 inhibitor might be preferable to a thiazolidinedione if further weight gain would cause significant problems, a thiazolidinedione is contraindicated, or the person has had a poor response to a thiazolidinedione.

Octreotide is utilized to treat high output pancreatic fistulae by reducing exocrine pancreatic secretions, although parenteral feeding is the most effective treatment. It is also used to treat variceal bleeding and acromegaly.

Octreotide inhibits the release of growth hormone and insulin from the pancreas. Additionally, somatostatin, which is released by the hypothalamus, triggers a negative feedback response on growth hormone.

Somatostatin: The Inhibitor Hormone

Somatostatin, also known as growth hormone inhibiting hormone (GHIH), is a hormone produced by delta cells found in the pancreas, pylorus, and duodenum. Its main function is to inhibit the secretion of growth hormone, insulin, and glucagon. It also decreases acid and pepsin secretion, as well as pancreatic enzyme secretion. Additionally, somatostatin inhibits the trophic effects of gastrin and stimulates gastric mucous production.

Somatostatin analogs are commonly used in the management of acromegaly, a condition characterized by excessive growth hormone secretion. These analogs work by inhibiting growth hormone secretion, thereby reducing the symptoms associated with acromegaly.

The secretion of somatostatin is regulated by various factors. Its secretion increases in response to fat, bile salts, and glucose in the intestinal lumen, as well as glucagon. On the other hand, insulin decreases the secretion of somatostatin.

In summary, somatostatin plays a crucial role in regulating the secretion of various hormones and enzymes in the body. Its inhibitory effects on growth hormone, insulin, and glucagon make it an important hormone in the management of certain medical conditions.

The secretion of adrenaline is primarily carried out by the adrenal medulla. A patient with a phaeochromocytoma, a type of cancer that affects the adrenal medulla, may experience symptoms such as tachycardia, headaches, and sweating due to excess adrenaline production.

The adrenal cortex, which surrounds the adrenal medulla, is not involved in adrenaline synthesis. It is responsible for producing mineralocorticoids, glucocorticoids, and androgens.

The medulla oblongata, located in the brainstem, regulates essential bodily functions but is not responsible for adrenaline secretion.

The parathyroid gland, which produces parathyroid hormone to regulate calcium metabolism, is not related to adrenaline secretion.

The Function of Adrenal Medulla

The adrenal medulla is responsible for producing almost all of the adrenaline in the body, along with small amounts of noradrenaline. Essentially, it is a specialized and enlarged sympathetic ganglion. This gland plays a crucial role in the body’s response to stress and danger, as adrenaline is a hormone that prepares the body for the fight or flight response. When the body perceives a threat, the adrenal medulla releases adrenaline into the bloodstream, which increases heart rate, blood pressure, and respiration, while also dilating the pupils and increasing blood flow to the muscles. This response helps the body to react quickly and effectively to danger. Overall, the adrenal medulla is an important component of the body’s stress response system.

When TSH receptor antibodies are present, they stimulate the thyroid to produce T4. This results in a decrease in TSH levels due to negative feedback on the pituitary. However, in cases where hyperthyroidism is caused by pregnancy, the TSH levels are usually elevated.

Understanding Thyroid Disease and its Management

Thyroid disease can present with various manifestations, which can be classified based on the presence or absence of clinical signs of thyroid dysfunction and the presence of a mass. To assess thyroid disease, a thorough history and examination, including ultrasound, are necessary. If a nodule is identified, it should be sampled through an image-guided fine needle aspiration. Radionucleotide scanning is not very useful.

Thyroid tumors can be papillary, follicular, anaplastic, medullary, or lymphoma. Multinodular goitre is a common reason for presentation, and if the patient is asymptomatic and euthyroid, they can be reassured. However, if they have compressive symptoms, surgery is required, and total thyroidectomy is the best option. Patients with endocrine dysfunction are initially managed by physicians, and surgery may be offered alongside radioiodine for those with Graves disease that fails with medical management or in patients who prefer not to be irradiated. Patients with hypothyroidism do not generally get offered a thyroidectomy.

Complications following surgery include anatomical damage to the recurrent laryngeal nerve, bleeding, and damage to the parathyroid glands resulting in hypocalcaemia. For further information, the Association of Clinical Biochemistry guidelines for thyroid function tests and the British Association of Endocrine Surgeons website can be consulted.

Excessive growth hormone can cause prognathism, spade-like hands, and tall stature. Patients may experience discomfort due to ill-fitting hats or shoes, as well as joint pain, headaches, and visual issues. It is important to note that gigantism occurs when there is an excess of growth hormone secretion before growth plate fusion, while acromegaly occurs when there is an excess of secretion after growth plate fusion.

Understanding Growth Hormone and Its Functions

Growth hormone (GH) is a hormone produced by the somatotroph cells in the anterior pituitary gland. It plays a crucial role in postnatal growth and development, as well as in regulating protein, lipid, and carbohydrate metabolism. GH acts on a transmembrane receptor for growth factor, leading to receptor dimerization and direct or indirect effects on tissues via insulin-like growth factor 1 (IGF-1), which is primarily secreted by the liver.

GH secretion is regulated by various factors, including growth hormone releasing hormone (GHRH), fasting, exercise, and sleep. Conversely, glucose and somatostatin can decrease GH secretion. Disorders associated with GH include acromegaly, which results from excess GH, and GH deficiency, which can lead to short stature.

In summary, GH is a vital hormone that plays a significant role in growth and metabolism. Understanding its functions and regulation can help in the diagnosis and treatment of GH-related disorders.

Thyroid Disorders and their Differentiation

Thyroid disorders are a common occurrence, and their diagnosis is crucial for effective treatment. One such disorder is Graves’ disease, which is characterized by a goitre with a bruit. Unlike MNG, Graves’ disease is associated with angiogenesis and thyroid follicular hypertrophy. Other signs of Graves’ disease include eye signs such as conjunctival oedema, exophthalmos, and proptosis. Additionally, pretibial myxoedema is a dermatological manifestation of this disease.

DeQuervain’s thyroiditis is another thyroid disorder that follows a viral infection and is characterized by painful thyroiditis. Hashimoto’s thyroiditis, on the other hand, is a chronic autoimmune degradation of the thyroid. Multinodular goitre (MNG) is the most common form of thyroid disorder, leading to the formation of multiple nodules over the gland. Lastly, a toxic thyroid nodule is a solitary lesion on the thyroid that produces excess thyroxine.

In conclusion, the different types of thyroid disorders and their symptoms is crucial for accurate diagnosis and effective treatment.

The onset of action and peak of NPH and regular insulin are a result of the combination of both human recombinant insulin preparations in the mixture.

Understanding Insulin Therapy

Insulin therapy has been a game-changer in the management of diabetes mellitus since its development in the 1920s. It remains the only available treatment for type 1 diabetes mellitus (T1DM) and is widely used in type 2 diabetes mellitus (T2DM) when oral hypoglycemic agents fail to provide adequate control. However, understanding the different types of insulin can be overwhelming, and it is crucial to have a basic grasp to avoid potential harm to patients.

Insulin can be classified by manufacturing process, duration of action, and type of insulin analogues. Patients often require a combination of preparations to ensure stable glycemic control throughout the day. Rapid-acting insulin analogues act faster and have a shorter duration of action than soluble insulin and may be used as the bolus dose in ‘basal-bolus’ regimes. Short-acting insulins, such as Actrapid and Humulin S, may also be used as the bolus dose in ‘basal-bolus’ regimes. Intermediate-acting insulins, like isophane insulin, are often used in a premixed formulation with long-acting insulins, such as insulin determir and insulin glargine, given once or twice daily. Premixed preparations combine intermediate-acting insulin with either a rapid-acting insulin analogue or soluble insulin.

The vast majority of patients administer insulin subcutaneously, and it is essential to rotate injection sites to prevent lipodystrophy. Insulin pumps are available, which delivers a continuous basal infusion and a patient-activated bolus dose at meal times. Intravenous insulin is used for patients who are acutely unwell, such as those with diabetic ketoacidosis. Inhaled insulin is available but not widely used, and oral insulin analogues are in development but have considerable technical hurdles to clear. Overall, understanding insulin therapy is crucial for healthcare professionals to provide safe and effective care for patients with diabetes mellitus.

DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors, thiazolidinediones, and sulfonylureas are all medications used to treat diabetes. DPP-4 inhibitors work by inhibiting the breakdown of incretins such as GLP-1 and GIP, which are released in response to food and help to lower blood glucose levels. GLP-1 agonists directly stimulate incretin receptors, while SGLT-2 inhibitors increase the urinary secretion of glucose. Thiazolidinediones stimulate intracellular signaling molecules responsible for glucose and lipid metabolism, and sulfonylureas stimulate beta cells to secrete more insulin. However, sulfonylureas may be less effective in long-standing diabetes as many beta cells may no longer function properly.

Diabetes mellitus is a condition that has seen the development of several drugs in recent years. One hormone that has been the focus of much research is glucagon-like peptide-1 (GLP-1), which is released by the small intestine in response to an oral glucose load. In type 2 diabetes mellitus (T2DM), insulin resistance and insufficient B-cell compensation occur, and the incretin effect, which is largely mediated by GLP-1, is decreased. GLP-1 mimetics, such as exenatide and liraglutide, increase insulin secretion and inhibit glucagon secretion, resulting in weight loss, unlike other medications. They are sometimes used in combination with insulin in T2DM to minimize weight gain. Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as vildagliptin and sitagliptin, increase levels of incretins by decreasing their peripheral breakdown, are taken orally, and do not cause weight gain. Nausea and vomiting are the major adverse effects of GLP-1 mimetics, and the Medicines and Healthcare products Regulatory Agency has issued specific warnings on the use of exenatide, reporting that it has been linked to severe pancreatitis in some patients. NICE guidelines suggest that a DPP-4 inhibitor might be preferable to a thiazolidinedione if further weight gain would cause significant problems, a thiazolidinedione is contraindicated, or the person has had a poor response to a thiazolidinedione.

Aldosterone is produced in the zona glomerulosa of the adrenal gland.

Renin is released by juxtaglomerular cells located in the nephron.

ACE is produced by the pulmonary endothelium in the lungs.

The adrenal gland is composed of the zona glomerulosa, fasciculata, and reticularis.

Glucocorticoids are produced in the zona fasciculata.

Adrenal Physiology: Medulla and Cortex

The adrenal gland is composed of two main parts: the medulla and the cortex. The medulla is responsible for secreting the catecholamines noradrenaline and adrenaline, which are released in response to sympathetic nervous system stimulation. The chromaffin cells of the medulla are innervated by the splanchnic nerves, and the release of these hormones is triggered by the secretion of acetylcholine from preganglionic sympathetic fibers. Phaeochromocytomas, which are tumors derived from chromaffin cells, can cause excessive secretion of both adrenaline and noradrenaline.

The adrenal cortex is divided into three distinct zones: the zona glomerulosa, zona fasciculata, and zona reticularis. Each zone is responsible for secreting different hormones. The outer zone, zona glomerulosa, secretes aldosterone, which regulates electrolyte balance and blood pressure. The middle zone, zona fasciculata, secretes glucocorticoids, which are involved in the regulation of metabolism, immune function, and stress response. The inner zone, zona reticularis, secretes androgens, which are involved in the development and maintenance of male sex characteristics.

Most of the hormones secreted by the adrenal cortex, including glucocorticoids and aldosterone, are bound to plasma proteins in the circulation. Glucocorticoids are inactivated and excreted by the liver. Understanding the physiology of the adrenal gland is important for the diagnosis and treatment of various endocrine disorders.

The patient is exhibiting symptoms consistent with a state of elevated cortisol levels, known as Cushing syndrome. These symptoms include recent weight gain, a round face (moon face), abdominal striae, high blood pressure, and truncal obesity. Cushing syndrome can have various causes, including the use of glucocorticoids or an ectopic ACTH secretion.

Elevated cortisol levels can lead to an increase in blood glucose levels, putting individuals at risk for hyperglycemia and diabetes. Cortisol can also suppress the immune system, inhibiting the production of prostaglandins, leukotrienes, and interleukin-2, and decreasing the adhesion of white blood cells. Additionally, cortisol can up-regulate alpha-1-adrenoceptors on arterioles, resulting in high blood pressure. High cortisol levels can also decrease osteoblast activity, leading to weakened bones, and reduce fibroblast activity and collagen synthesis, resulting in delayed wound healing. The abdominal striae seen in patients with high cortisol levels are typically due to decreased collagen synthesis.

Causes of Cushing’s Syndrome

Cushing’s syndrome is a condition that can be caused by both endogenous and exogenous factors. However, it is important to note that exogenous causes, such as the use of glucocorticoid therapy, are more common than endogenous ones. The condition can be classified into two categories: ACTH dependent and ACTH independent causes.

ACTH dependent causes of Cushing’s syndrome include Cushing’s disease, which is caused by a pituitary tumor secreting ACTH and producing adrenal hyperplasia. Ectopic ACTH production, which is caused by small cell lung cancer, is another ACTH dependent cause. On the other hand, ACTH independent causes include iatrogenic factors such as steroid use, adrenal adenoma, adrenal carcinoma, Carney complex, and micronodular adrenal dysplasia.

In some cases, a condition called Pseudo-Cushing’s can mimic Cushing’s syndrome. This is often caused by alcohol excess or severe depression and can cause false positive results in dexamethasone suppression tests or 24-hour urinary free cortisol tests. To differentiate between Cushing’s syndrome and Pseudo-Cushing’s, an insulin stress test may be used.

Insulin stimulates the Na+/K+ ATPase pump, which leads to a decrease in serum potassium levels. This is the primary treatment for type 1 diabetes, where the pancreas no longer produces insulin, causing high blood sugar levels. Injectable insulin allows glucose to enter cells, and insulin also increases cellular uptake of potassium while decreasing serum potassium levels. Insulin also stimulates muscle protein synthesis, reducing muscle protein loss. Insulin is secreted in response to hyperglycaemia, where high blood sugar levels trigger the beta cells of the pancreas to release insulin in healthy individuals.

Insulin is a hormone produced by the pancreas that plays a crucial role in regulating the metabolism of carbohydrates and fats in the body. It works by causing cells in the liver, muscles, and fat tissue to absorb glucose from the bloodstream, which is then stored as glycogen in the liver and muscles or as triglycerides in fat cells. The human insulin protein is made up of 51 amino acids and is a dimer of an A-chain and a B-chain linked together by disulfide bonds. Pro-insulin is first formed in the rough endoplasmic reticulum of pancreatic beta cells and then cleaved to form insulin and C-peptide. Insulin is stored in secretory granules and released in response to high levels of glucose in the blood. In addition to its role in glucose metabolism, insulin also inhibits lipolysis, reduces muscle protein loss, and increases cellular uptake of potassium through stimulation of the Na+/K+ ATPase pump.

Leptin is the hormone that lowers appetite, while ghrelin is the hormone that increases appetite. Leptin is produced by adipose tissue and plays a crucial role in regulating feelings of fullness and satiety. Mutations that affect leptin signaling can lead to severe childhood-onset obesity. On the other hand, ghrelin is known as the hunger hormone and stimulates appetite. However, decreased ghrelin synthesis does not cause obesity. Insulin is an anabolic hormone that promotes glucose uptake and lipogenesis, while obestatin’s role in satiety is still controversial.

The Physiology of Obesity: Leptin and Ghrelin

Leptin is a hormone produced by adipose tissue that plays a crucial role in regulating body weight. It acts on the hypothalamus, specifically on the satiety centers, to decrease appetite and induce feelings of fullness. In cases of obesity, where there is an excess of adipose tissue, leptin levels are high. Leptin also stimulates the release of melanocyte-stimulating hormone (MSH) and corticotrophin-releasing hormone (CRH), which further contribute to the regulation of appetite. On the other hand, low levels of leptin stimulate the release of neuropeptide Y (NPY), which increases appetite.

Ghrelin, on the other hand, is a hormone that stimulates hunger. It is mainly produced by the P/D1 cells lining the fundus of the stomach and epsilon cells of the pancreas. Ghrelin levels increase before meals, signaling the body to prepare for food intake, and decrease after meals, indicating that the body has received enough nutrients.

In summary, the balance between leptin and ghrelin plays a crucial role in regulating appetite and body weight. In cases of obesity, there is an imbalance in this system, with high levels of leptin and potentially disrupted ghrelin signaling, leading to increased appetite and weight gain.

SGLT2 inhibitors are known as gliflozins.

Sulfonylurea refers to tolbutamide.

GLP-1 receptor agonist is exenatide.

DPP-4 inhibitor is linagliptin.

Understanding SGLT-2 Inhibitors

SGLT-2 inhibitors are medications that work by blocking the reabsorption of glucose in the kidneys, leading to increased excretion of glucose in the urine. This mechanism of action helps to lower blood sugar levels in patients with type 2 diabetes mellitus. Examples of SGLT-2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin.

However, it is important to note that SGLT-2 inhibitors can also have adverse effects. Patients taking these medications may be at increased risk for urinary and genital infections due to the increased glucose in the urine. Fournier’s gangrene, a rare but serious bacterial infection of the genital area, has also been reported. Additionally, there is a risk of normoglycemic ketoacidosis, a condition where the body produces high levels of ketones even when blood sugar levels are normal. Finally, patients taking SGLT-2 inhibitors may be at increased risk for lower-limb amputations, so it is important to closely monitor the feet.

Despite these potential risks, SGLT-2 inhibitors can also have benefits. Patients taking these medications often experience weight loss, which can be beneficial for those with type 2 diabetes mellitus. Overall, it is important for patients to discuss the potential risks and benefits of SGLT-2 inhibitors with their healthcare provider before starting treatment.

Clusters of microcalcification, known as psammoma bodies, are frequently observed in papillary carcinomas.

Thyroid cancer rarely causes hyperthyroidism or hypothyroidism as it does not usually secrete thyroid hormones. The most common type of thyroid cancer is papillary carcinoma, which is often found in young females and has an excellent prognosis. Follicular carcinoma is less common, while medullary carcinoma is a cancer of the parafollicular cells that secrete calcitonin and is associated with multiple endocrine neoplasia type 2. Anaplastic carcinoma is rare and not responsive to treatment, causing pressure symptoms. Lymphoma is also rare and associated with Hashimoto’s thyroiditis.

Management of papillary and follicular cancer involves a total thyroidectomy followed by radioiodine to kill residual cells. Yearly thyroglobulin levels are monitored to detect early recurrent disease. Papillary carcinoma usually contains a mixture of papillary and colloidal filled follicles, while follicular adenoma presents as a solitary thyroid nodule and malignancy can only be excluded on formal histological assessment. Follicular carcinoma may appear macroscopically encapsulated, but microscopically capsular invasion is seen. Medullary carcinoma is associated with raised serum calcitonin levels and familial genetic disease in up to 20% of cases. Anaplastic carcinoma is most common in elderly females and is treated by resection where possible, with palliation achieved through isthmusectomy and radiotherapy. Chemotherapy is ineffective.